Cargando…

Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana

It is established that addition of systemic therapy to locoregional treatment for breast cancer improves survival. However, reliable data are lacking about the outcomes of such treatment in women with breast cancer in low middle-income countries. We compared the outcomes of treatment in patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayettey Anie, Hannah, Yarney, Joel, Sanuade, Olutobi, Awasthi, Shivanshu, Ndanu, Tom Akuetteh, Parekh, Akash D., Aidoo, Charles, Dadzie, Mary Ann, Vanderpuye, Verna, Yamoah, Kosj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457842/
https://www.ncbi.nlm.nih.gov/pubmed/34156868
http://dx.doi.org/10.1200/GO.20.00664
_version_ 1784571189928132608
author Ayettey Anie, Hannah
Yarney, Joel
Sanuade, Olutobi
Awasthi, Shivanshu
Ndanu, Tom Akuetteh
Parekh, Akash D.
Aidoo, Charles
Dadzie, Mary Ann
Vanderpuye, Verna
Yamoah, Kosj
author_facet Ayettey Anie, Hannah
Yarney, Joel
Sanuade, Olutobi
Awasthi, Shivanshu
Ndanu, Tom Akuetteh
Parekh, Akash D.
Aidoo, Charles
Dadzie, Mary Ann
Vanderpuye, Verna
Yamoah, Kosj
author_sort Ayettey Anie, Hannah
collection PubMed
description It is established that addition of systemic therapy to locoregional treatment for breast cancer improves survival. However, reliable data are lacking about the outcomes of such treatment in women with breast cancer in low middle-income countries. We compared the outcomes of treatment in patients who had received neoadjuvant chemotherapy (NACT) or adjuvant chemotherapy and examined the factors associated with breast cancer recurrence and survival at the National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital, Ghana. METHODS: This was a retrospective cohort study. The medical charts of women with breast cancer managed at the National Radiotherapy Oncology and Nuclear Medicine Centre from 2005 to 2014 were reviewed. A total of 388 patients with a median follow-up of 48 months were included in the study. Logistic regression was used to estimate the risk of recurrence. Survival was estimated using cox proportional hazards model. All models were adjusted with clinicopathologic variables. A P value of < .05 was considered statistically significant. RESULTS: Fifty-nine percent received adjuvant chemotherapy. In an adjusted logistic model, no difference was observed in locoregional recurrence between patients receiving NACT compared with those receiving adjuvant chemotherapy (odds ratio = 1.05; 95% CI, 0.44 to 2.47). However, NACT recipients had a higher likelihood of distant recurrence (odds ratio = 1.97; 95% CI, 1.24 to 3.15). In a multivariable analysis, no differences were observed in overall survival between the two chemotherapy groups (hazard ratio = 1.43; 95% CI, 0.91 to 2.26). CONCLUSION: NACT yields similar outcomes compared with adjuvant chemotherapy; however, recipients of NACT with advanced disease may have more distant failures. Early detection in a resource-limited setting is therefore crucial to optimal outcomes, significantly limiting recurrence and improving survival.
format Online
Article
Text
id pubmed-8457842
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-84578422021-09-23 Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana Ayettey Anie, Hannah Yarney, Joel Sanuade, Olutobi Awasthi, Shivanshu Ndanu, Tom Akuetteh Parekh, Akash D. Aidoo, Charles Dadzie, Mary Ann Vanderpuye, Verna Yamoah, Kosj JCO Glob Oncol ORIGINAL REPORTS It is established that addition of systemic therapy to locoregional treatment for breast cancer improves survival. However, reliable data are lacking about the outcomes of such treatment in women with breast cancer in low middle-income countries. We compared the outcomes of treatment in patients who had received neoadjuvant chemotherapy (NACT) or adjuvant chemotherapy and examined the factors associated with breast cancer recurrence and survival at the National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital, Ghana. METHODS: This was a retrospective cohort study. The medical charts of women with breast cancer managed at the National Radiotherapy Oncology and Nuclear Medicine Centre from 2005 to 2014 were reviewed. A total of 388 patients with a median follow-up of 48 months were included in the study. Logistic regression was used to estimate the risk of recurrence. Survival was estimated using cox proportional hazards model. All models were adjusted with clinicopathologic variables. A P value of < .05 was considered statistically significant. RESULTS: Fifty-nine percent received adjuvant chemotherapy. In an adjusted logistic model, no difference was observed in locoregional recurrence between patients receiving NACT compared with those receiving adjuvant chemotherapy (odds ratio = 1.05; 95% CI, 0.44 to 2.47). However, NACT recipients had a higher likelihood of distant recurrence (odds ratio = 1.97; 95% CI, 1.24 to 3.15). In a multivariable analysis, no differences were observed in overall survival between the two chemotherapy groups (hazard ratio = 1.43; 95% CI, 0.91 to 2.26). CONCLUSION: NACT yields similar outcomes compared with adjuvant chemotherapy; however, recipients of NACT with advanced disease may have more distant failures. Early detection in a resource-limited setting is therefore crucial to optimal outcomes, significantly limiting recurrence and improving survival. Wolters Kluwer Health 2021-06-22 /pmc/articles/PMC8457842/ /pubmed/34156868 http://dx.doi.org/10.1200/GO.20.00664 Text en © 2021 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle ORIGINAL REPORTS
Ayettey Anie, Hannah
Yarney, Joel
Sanuade, Olutobi
Awasthi, Shivanshu
Ndanu, Tom Akuetteh
Parekh, Akash D.
Aidoo, Charles
Dadzie, Mary Ann
Vanderpuye, Verna
Yamoah, Kosj
Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
title Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
title_full Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
title_fullStr Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
title_full_unstemmed Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
title_short Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
title_sort neoadjuvant or adjuvant chemotherapy for breast cancer in sub-saharan africa: a retrospective analysis of recurrence and survival in women treated for breast cancer at the korle bu teaching hospital in ghana
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457842/
https://www.ncbi.nlm.nih.gov/pubmed/34156868
http://dx.doi.org/10.1200/GO.20.00664
work_keys_str_mv AT ayetteyaniehannah neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT yarneyjoel neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT sanuadeolutobi neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT awasthishivanshu neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT ndanutomakuetteh neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT parekhakashd neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT aidoocharles neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT dadziemaryann neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT vanderpuyeverna neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana
AT yamoahkosj neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana